SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy
Clinical trial NCT07524374 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07524374
- Sponsor
- Zhigang Li
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-15
- Primary completion
- 2027-09-30
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.